Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Enigma negatively regulates p53 through MDM2 and promotes tumor cell survival in mice
Cho-Rok Jung, … , Seung-Moo Noh, Dong-Soo Im
Cho-Rok Jung, … , Seung-Moo Noh, Dong-Soo Im
Published November 8, 2010
Citation Information: J Clin Invest. 2010;120(12):4493-4506. https://doi.org/10.1172/JCI42674.
View: Text | PDF
Research Article Oncology

Enigma negatively regulates p53 through MDM2 and promotes tumor cell survival in mice

  • Text
  • PDF
Abstract

The human E3 ubiquitin ligase murine double minute 2 (MDM2) targets the tumor suppressor p53 for ubiquitination and degradation but also promotes its own ubiquitination and subsequent degradation. As the balance between MDM2 and p53 levels plays a crucial role in regulating cell proliferation and apoptosis, we sought to identify factors selectively inhibiting MDM2 self-ubiquitination. Here we have shown that the LIM domain protein Enigma directly interacts with MDM2 to form a ternary complex with p53 in vitro and in human hepatoma and colon carcinoma cell lines and mouse embryonic fibroblasts. We found that Enigma elicited p53 degradation by inhibiting MDM2 self-ubiquitination and increasing its ubiquitin ligase activity toward p53 in cells. Moreover, mitogenic stimuli such as serum, FGF, and HGF increased Enigma transcription via induction of serum response factor (SRF), leading to MDM2 stabilization and subsequent p53 degradation. We observed similar results in the livers of mice treated with HGF. In humans, we found SRF and Enigma coexpressed with MDM2 but not p53 in several liver and stomach tumors. Finally, we showed that Enigma promoted cell survival and chemoresistance by suppressing p53-mediated apoptosis in both cell lines and a mouse xenograft model. Our findings suggest a role for Enigma in tumorigenesis and uncover a mechanism whereby mitogens attenuate p53 antiproliferative activity through an SRF/Enigma/MDM2 pathway.

Authors

Cho-Rok Jung, Jung Hwa Lim, Yoonjung Choi, Dae-Ghon Kim, Koo Jeong Kang, Seung-Moo Noh, Dong-Soo Im

×

Figure 2

Enigma interacts with p53 through MDM2 in vitro and in vivo.

Options: View larger image (or click on image) Download as PowerPoint
Enigma interacts with p53 through MDM2 in vitro and in vivo.
(A) We immu...
(A) We immunoprecipitated and/or immunoblotted HCT116p53+/+ or p53–/– cells. (B) We transduced Mdm2–/–p53–/– (Mdm2–/–) and Mdm2+/+p53–/– (Mdm2+/+) MEFs with Ad-p53 at an MOI of 100 and incubated them for 24 hours before IP and/or IB. (C) We mixed His-MDM2 (1 μg), Enigma (0.5 μg), EniΔLIM3 (0.5 μg), GST-p53 (1 μg), and/or GST (1 μg) proteins for IP or GST pull-down and IB. (D and E) Various GST-MDM2 fusion (D) or F-Enigma (E) vectors are illustrated in the top panel. (D) We transfected 293–F-Enigma cells with the indicated vectors (5 μg each), and performed GST pull-down/IB and IB at 24 hours after transfection. MDM2 domains necessary for the interaction with Enigma and for binding to p53 are indicated at the top. The RING domain of MDM2 is shown in gray. (E) We transfected 293T cells with or without various F-Enigma (5 μg each) and with GST-MDM2 (5 μg each) vectors and incubated them for 24 hours before IB and IP/IB. The PDZ and 3 LIM domains of Enigma and the Enigma domain required for binding to MDM2 are shown at the top. The results from the binding assay are summarized on the right of the top panels in D and E. (F) We transfected HLK3 cells with the indicated vectors (5 μg each), which are illustrated in E, and incubated them for 48 hours before GST pull-down/IB and IB. (G) Schematic illustration of the Enigma-MDM2-p53 ternary complex.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts